Anhui Fengyuan Pharmaceutical 관리

관리 기준 확인 3/4

Anhui Fengyuan Pharmaceutical CEO는 Tianle Ru, Jul2022 에 임명되었습니다 의 임기는 2.33 년입니다. 는 CN¥ 9.00M 가치에 해당하는 회사 주식의 0.3% 직접 소유합니다. 9.00M. 경영진과 이사회의 평균 재임 기간은 각각 7.7 년과 5.4 년입니다.

주요 정보

Tianle Ru

최고 경영자

CN¥862.0k

총 보상

CEO 급여 비율	n/a
CEO 임기	2.3yrs
CEO 소유권	0.3%
경영진 평균 재임 기간	7.7yrs
이사회 평균 재임 기간	5.4yrs

최근 관리 업데이트

Recent updates

Anhui Fengyuan Pharmaceutical's (SZSE:000153) Anemic Earnings Might Be Worse Than You Think

May 07

Anhui Fengyuan Pharmaceutical Co., Ltd.'s (SZSE:000153) Business And Shares Still Trailing The Market

Apr 17

CEO

Tianle Ru (39 yo)

2.3yrs

테뉴어

CN¥862,000

보상

Mr. Tianle Ru is General Manager and Director of Anhui Fengyuan Pharmaceutical Co., Ltd since July 07, 2022.

리더십 팀

이름	위치	테뉴어	보상	소유권
Tianle Ru	GM & Director	2.3yrs	CN¥862.00k	0.30% CN¥ 9.0m
Jun Li	Deputy GM & Financial Director	7.7yrs	CN¥420.00k	0.12% CN¥ 3.5m
Shaoyi Zhang	Deputy GM & Director	17.6yrs	CN¥588.00k	0.090% CN¥ 2.7m
Zhenhong Lu	Deputy GM & Director	4.2yrs	CN¥354.00k	0.11% CN¥ 3.2m
Jun Zhang	Secretary of the Board & Non-Independent Director	26.1yrs	CN¥336.00k	0.14% CN¥ 4.1m
Guo Kun Li	Deputy General Manager	11.6yrs	CN¥392.00k	0.060% CN¥ 1.8m
Shuang Qing Yin	Deputy General Manager	5.4yrs	CN¥380.00k	0.090% CN¥ 2.7m

7.7yrs

평균 재임 기간

52yo

평균 연령

경험이 풍부한 관리: 000153 의 관리팀은 노련하고 경험 (평균 재직 기간 7.7 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Tianle Ru	GM & Director	2.3yrs	CN¥862.00k	0.30% CN¥ 9.0m
Shaoyi Zhang	Deputy GM & Director	10.1yrs	CN¥588.00k	0.090% CN¥ 2.7m
Zhenhong Lu	Deputy GM & Director	8.7yrs	CN¥354.00k	0.11% CN¥ 3.2m
Jun Zhang	Secretary of the Board & Non-Independent Director	4.5yrs	CN¥336.00k	0.14% CN¥ 4.1m
Hongman He	Chairman of the Board	16.7yrs	CN¥920.00k	0.45% CN¥ 13.5m
Yue'e Hu	Chairman of Supervisory Board	2.3yrs	CN¥420.00k	데이터 없음
Weidong Zhu	Independent Director	5.4yrs	CN¥60.00k	데이터 없음
Jiemiao Chen	Independent Director	5.4yrs	CN¥60.00k	데이터 없음
Jinsheng Hu	Non-Employee Supervisor	5.4yrs	데이터 없음	데이터 없음
Jinchao Duan	Director	2.3yrs	CN¥344.00k	0.060% CN¥ 1.8m
Cisheng Wu	Independent Director	2.3yrs	CN¥60.00k	데이터 없음
Hui Yan Sun	Supervisor	5.4yrs	데이터 없음	데이터 없음

5.4yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 이사회: 000153 의 이사회는 경험(평균 재직 기간 5.4 년)으로 간주됩니다.

Anhui Fengyuan Pharmaceutical 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Anhui Fengyuan Pharmaceutical Co., Ltd., Annual General Meeting, May 22, 2024

Less than half of directors are independent

High number of new directors

Anhui Fengyuan Pharmaceutical Co., Ltd. Announces Management Appointments

High number of new and inexperienced directors

Recent updates

New minor risk - Earnings quality

Third quarter 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.085 in 3Q 2023)

Investor sentiment improves as stock rises 16%

Anhui Fengyuan Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Investor sentiment improves as stock rises 21%

Now 22% overvalued after recent price rise

New minor risk - Earnings quality

Second quarter 2024 earnings released: EPS: CN¥0.12 (vs CN¥0.12 in 2Q 2023)

Anhui Fengyuan Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024

Dividend increased to CN¥0.15

Anhui Fengyuan Pharmaceutical Co., Ltd. Announces 2023 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 07 June 2024

Anhui Fengyuan Pharmaceutical's (SZSE:000153) Anemic Earnings Might Be Worse Than You Think

Anhui Fengyuan Pharmaceutical Co., Ltd., Annual General Meeting, May 22, 2024

Anhui Fengyuan Pharmaceutical Co., Ltd. Proposes Final Cash Dividend (Tax Included) for 2023

First quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.14 in 1Q 2023)

Now 23% overvalued

Anhui Fengyuan Pharmaceutical Co., Ltd.'s (SZSE:000153) Business And Shares Still Trailing The Market

Anhui Fengyuan Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Investor sentiment deteriorates as stock falls 18%

Anhui Fengyuan Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024

Third quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.12 in 3Q 2022)

New minor risk - Earnings quality

Second quarter 2023 earnings released: EPS: CN¥0.17 (vs CN¥0.17 in 2Q 2022)

Anhui Fengyuan Pharmaceutical Announces Cash Dividend for 2022

Full year 2022 earnings released: EPS: CN¥0.49 (vs CN¥0.37 in FY 2021)

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Investor sentiment improved over the past week

Investor sentiment improved over the past week

High number of new directors

Third quarter 2022 earnings released: EPS: CN¥0.12 (vs CN¥0.085 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.17 (vs CN¥0.12 in 2Q 2021)

Anhui Fengyuan Pharmaceutical Co., Ltd. Announces Management Appointments

Anhui Fengyuan Pharmaceutical Co., Ltd. Announces Cash Dividend for A Shares for the Year 2021, Payable on 05 July 2022

Anhui Fengyuan Pharmaceutical Co., Ltd. Approves Cash Distribution for 2021

Anhui Fengyuan Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2021

First quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Third quarter 2021 earnings released: EPS CN¥0.085 (vs CN¥0.041 in 3Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.12 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥0.33 (vs CN¥0.26 in FY 2019)

Investor sentiment improved over the past week

Anhui Fengyuan Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Apr 23, 2021

New 90-day low: CN¥6.62

Investor sentiment deteriorated over the past week

New 90-day low: CN¥7.79

New 90-day low: CN¥8.07

New 90-day low: CN¥8.22

Third quarter earnings released

First half earnings released

Anhui Fengyuan Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

New 90-day high - CN¥12.49

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령